Send us a Message



 Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer VCMap
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
PhenoMiner Database Result        View data table  |  Download data table  |  View expanded data table        

Generate Chart For    
    (Chart displayed below)
Rat Strains
{{sample.term}}
Measurement Methods
{{method.term}}
Age
{{ageRange}}
Experimental Conditions
     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View expanded data table
# of AnimalsPhenotypeStrainSexValueUnitsConditionsRecord IDCondition 1aCondition 1bCondition 1cCondition 2Condition 3
12kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale9%control condition67708control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D3Wox2-D3Rat59)/Eurmale13%control condition67709control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat298-D1Rat90)/Eurmale14%control condition67710control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eurmale14%control condition67711control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale11%NG-nitroarginine methyl ester (50-150 mg/l) 67712NG-nitroarginine methyl ester (50-150 mg/l)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D3Wox2-D3Rat59)/Eurmale18%NG-nitroarginine methyl ester (50-150 mg/l) 67714NG-nitroarginine methyl ester (50-150 mg/l)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat298-D1Rat90)/Eurmale23%NG-nitroarginine methyl ester (50-150 mg/l) 67715NG-nitroarginine methyl ester (50-150 mg/l)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eurmale31%NG-nitroarginine methyl ester (50-150 mg/l) 67716NG-nitroarginine methyl ester (50-150 mg/l)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale15%right nephrectomy67717right nephrectomy
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D3Wox2-D3Rat59)/Eurmale20%right nephrectomy67718right nephrectomy
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat298-D1Rat90)/Eurmale23%right nephrectomy67719right nephrectomy
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eurmale27%right nephrectomy67720right nephrectomy
12kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale15%right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) 67722right nephrectomyNG-nitroarginine methyl ester (50-150 mg/l)
11kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D3Wox2-D3Rat59)/Eurmale39%right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) 67723right nephrectomyNG-nitroarginine methyl ester (50-150 mg/l)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat298-D1Rat90)/Eurmale37%right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) 67724right nephrectomyNG-nitroarginine methyl ester (50-150 mg/l)
5kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat475-D1Rat90)(D3Rat84-D3Rat59)/Eurmale64%right nephrectomy then NG-nitroarginine methyl ester (50-150 mg/l) 67725right nephrectomyNG-nitroarginine methyl ester (50-150 mg/l)
13percentage of study population developing chronic pancreatitis during a period of timeWBN/KobSlcmale69%controlled protein content diet67772controlled protein content diet
5percentage of study population developing chronic pancreatitis during a period of timeBN/CrlCrljmale0%controlled protein content diet67773controlled protein content diet
5percentage of study population developing chronic pancreatitis during a period of timeWBN/KobSlcmale100%controlled protein content diet67774controlled protein content diet
5percentage of study population developing chronic pancreatitis during a period of timeWBN/KobSlcmale100%controlled protein content diet67775controlled protein content diet
5percentage of study population developing chronic pancreatitis during a period of timeBN/CrlCrljmale0%controlled protein content diet67776controlled protein content diet
6percentage of study population developing chronic pancreatitis during a period of timeBN/CrlCrljmale0%controlled protein content diet67777controlled protein content diet
8count of superficial glomeruli directly contacting the kidney surfaceMWF/Fubmale2.9control condition67833control condition
8count of superficial glomeruli directly contacting the kidney surfaceSHR/Fubmale0control condition67834control condition
8count of superficial glomeruli not directly contacting the kidney surfaceMWF/Fubmale19.4control condition67827control condition
8count of superficial glomeruli not directly contacting the kidney surfaceSHR/Fubmale0.1control condition67831control condition
12percentage of study population developing cerebrovascular lesions during a period of timeSHRSP/Izmmale50%controlled sodium content drinking water (1 %) (for 14 days)65291controlled sodium content drinking water (1 %) (for 14 days)
10percentage of study population developing cerebrovascular lesions during a period of timeSHRSP/Izmfemale0%controlled sodium content drinking water (1 %) (for 14 days)65292controlled sodium content drinking water (1 %) (for 14 days)
12percentage of study population developing cerebrovascular lesions during a period of timeSHRSP/Izmmale100%controlled sodium content drinking water (1 %) (for 28 days)65294controlled sodium content drinking water (1 %) (for 28 days)
10percentage of study population developing cerebrovascular lesions during a period of timeSHRSP/Izmfemale60%controlled sodium content drinking water (1 %) (for 28 days)65295controlled sodium content drinking water (1 %) (for 28 days)
13percentage of study population developing cerebrovascular lesions during a period of timeSHRSP.WKY-(Klk1-D1Rat116)/Izmmale0%controlled sodium content drinking water (1 %) (for 14 days)65297controlled sodium content drinking water (1 %) (for 14 days)
9percentage of study population developing cerebrovascular lesions during a period of timeSHRSP.WKY-(Klk1-D1Rat116)/Izmfemale0%controlled sodium content drinking water (1 %) (for 14 days)65299controlled sodium content drinking water (1 %) (for 14 days)
13percentage of study population developing cerebrovascular lesions during a period of timeSHRSP.WKY-(Klk1-D1Rat116)/Izmmale0%controlled sodium content drinking water (1 %) (for 28 days)65300controlled sodium content drinking water (1 %) (for 28 days)
9percentage of study population developing cerebrovascular lesions during a period of timeSHRSP.WKY-(Klk1-D1Rat116)/Izmmale0%controlled sodium content drinking water (1 %) (for 28 days)65301controlled sodium content drinking water (1 %) (for 28 days)
22kidney glomerulus diameterBN/NHsdMcwifemale95umcontrolled sodium content diet (0.4 %) (for 35 days)67285controlled sodium content diet (0.4 %) (for 35 days)
16kidney glomerulus diameterSS/JrHsdMcwifemale117umcontrolled sodium content diet (0.4 %) (for 35 days)67286controlled sodium content diet (0.4 %) (for 35 days)
6artery wall thickness to artery total diameter ratioSS.SR-(D3Arb14-D3Mco36)(D7Mco19-D7Mco7)/Mcomale57.3%controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days)65736controlled sodium content diet (0.3 %) (between 10 and 12 days)controlled sodium content diet (2 %) (for 28 days)controlled sodium content diet (4 %) (between 46 and 48 days)
6artery wall thickness to artery total diameter ratioSS.SR-(D3Arb14-D3Mco36)/Mcomale55%controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days)65735controlled sodium content diet (0.3 %) (between 10 and 12 days)controlled sodium content diet (2 %) (for 28 days)controlled sodium content diet (4 %) (between 46 and 48 days)
3artery wall thickness to artery total diameter ratioSS.SR-(D7Mco19-D7Mco7)/Jrmale53.3%controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days)65737controlled sodium content diet (0.3 %) (between 10 and 12 days)controlled sodium content diet (2 %) (for 28 days)controlled sodium content diet (4 %) (between 46 and 48 days)
3artery wall thickness to artery total diameter ratioSS/Jrmale54%controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (for 28 days) then controlled sodium content diet (4 %) (between 46 and 48 days)65738controlled sodium content diet (0.3 %) (between 10 and 12 days)controlled sodium content diet (2 %) (for 28 days)controlled sodium content diet (4 %) (between 46 and 48 days)
8percentage of study population developing ventral prostate tumorous lesions during a period of timeF344/Jclmale50%control condition65824control condition
12percentage of study population developing ventral prostate tumorous lesions during a period of timeACI/SegHsdmale100%control condition65825control condition
12prostate tumorous lesion numberACI/SegHsdmale5.3control condition65822control condition
8prostate tumorous lesion numberF344/Jclmale1.5control condition65823control condition
12percentage of study population developing testis tumors during a period of timeACI/SegHsdmale92%control condition65840control condition
8percentage of study population developing testis tumors during a period of timeF344/Jclmale100%control condition65841control condition
12percentage of study population developing bilateral testis tumors during a period of timeACI/SegHsdmale25%control condition67948control condition
8percentage of study population developing bilateral testis tumors during a period of timeF344/Jclmale88%control condition67949control condition
8percentage of study population developing leukemia during a period of timeF344/Jclmale25%control condition66142control condition
12percentage of study population developing leukemia during a period of timeACI/SegHsdmale0%control condition66143control condition
12percentage of study population developing ventral prostate tumorous lesions with a solid structure during a period of timeACI/SegHsdmale92%control condition109885control condition
8percentage of study population developing ventral prostate tumorous lesions with a solid structure during a period of timeF344/Jclmale25%control condition109886control condition
12number of ventral prostate tumorous lesions with solid structureACI/SegHsdmale3control condition109887control condition
8number of ventral prostate tumorous lesions with solid structureF344/Jclmale0.4control condition109888control condition
12percentage of study population developing ventral prostate tumorous lesions with round, irregular size nuclei during a period of timeACI/SegHsdmale100%control condition109957control condition
8percentage of study population developing ventral prostate tumorous lesions with round, irregular size nuclei during a period of timeF344/Jclmale38%control condition109958control condition
12number of ventral prostate tumorous lesions with round, irregular size nucleiACI/SegHsdmale5.1control condition109959control condition
8number of ventral prostate tumorous lesions with round, irregular size nucleiF344/Jclmale1.3control condition109960control condition
8count of superficial glomeruli directly contacting the kidney surfaceMWF/FubRkbnot specified2.9control condition67601control condition
8count of superficial glomeruli directly contacting the kidney surfaceLEW/Rkbnot specified0control condition67602control condition
8count of superficial glomeruli not directly contacting the kidney surfaceMWF/FubRkbnot specified19.4control condition67599control condition
8count of superficial glomeruli not directly contacting the kidney surfaceLEW/Rkbnot specified6.3control condition67600control condition
15brain infarction volumeSHRSP.WKY-(D1Wox29-D1Arb21)/Izmmale66.4mm3control condition (for 153 days)65950control condition (for 153 days)
17brain infarction volumeSHRSP/Izmmale103.4mm3control condition (for 153 days)65951control condition (for 153 days)
7kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eurmale2%controlled hydrogen ion content drinking water (2.4-2.8 pH) 67951controlled hydrogen ion content drinking water (2.4-2.8 pH)
8kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat324-D1Rat156)/Eurmale15%controlled hydrogen ion content drinking water (2.4-2.8 pH) 67952controlled hydrogen ion content drinking water (2.4-2.8 pH)
8kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale6%controlled hydrogen ion content drinking water (2.4-2.8 pH) then NG-nitroarginine methyl ester (8-13 mg/kg/d) (for 126 days)67953controlled hydrogen ion content drinking water (2.4-2.8 pH) NG-nitroarginine methyl ester (8-13 mg/kg/d) (for 126 days)
9kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eurmale5%controlled hydrogen ion content drinking water (2.4-2.8 pH) then NG-nitroarginine methyl ester (8-13 mg/kg/d) (for 126 days)67954controlled hydrogen ion content drinking water (2.4-2.8 pH) NG-nitroarginine methyl ester (8-13 mg/kg/d) (for 126 days)
7kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat324-D1Rat156)/Eurmale16%controlled hydrogen ion content drinking water (2.4-2.8 pH) then NG-nitroarginine methyl ester (8-13 mg/kg/d) (for 126 days)67955controlled hydrogen ion content drinking water (2.4-2.8 pH) NG-nitroarginine methyl ester (8-13 mg/kg/d) (for 126 days)
8kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale5%controlled hydrogen ion content drinking water (2.4-2.8 pH) then unilateral nephrectomy67956controlled hydrogen ion content drinking water (2.4-2.8 pH) unilateral nephrectomy
10kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eurmale2%controlled hydrogen ion content drinking water (2.4-2.8 pH) then unilateral nephrectomy67957controlled hydrogen ion content drinking water (2.4-2.8 pH) unilateral nephrectomy
8kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat324-D1Rat156)/Eurmale9%controlled hydrogen ion content drinking water (2.4-2.8 pH) then unilateral nephrectomy67958controlled hydrogen ion content drinking water (2.4-2.8 pH) unilateral nephrectomy
11kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale13%controlled hydrogen ion content drinking water (2.4-2.8 pH) then unilateral nephrectomy then NG-nitroarginine methyl ester (11-15 mg/kg/d) (for 126 days)67959controlled hydrogen ion content drinking water (2.4-2.8 pH) unilateral nephrectomyNG-nitroarginine methyl ester (11-15 mg/kg/d) (for 126 days)
9kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eurmale8%controlled hydrogen ion content drinking water (2.4-2.8 pH) then unilateral nephrectomy then NG-nitroarginine methyl ester (11-15 mg/kg/d) (for 126 days)67960controlled hydrogen ion content drinking water (2.4-2.8 pH) unilateral nephrectomyNG-nitroarginine methyl ester (11-15 mg/kg/d) (for 126 days)
15kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale6%controlled hydrogen ion content drinking water (2.4-2.8 pH) 68044controlled hydrogen ion content drinking water (2.4-2.8 pH)
15kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D17Rat117-D17Arb5)(D17Rat180-D17Rat51)/Eurmale5%controlled hydrogen ion content drinking water (2.4-2.8 pH) 68045controlled hydrogen ion content drinking water (2.4-2.8 pH)
15kidney sclerotic glomeruli count to total glomeruli count ratioFHH/Eurmale13%controlled hydrogen ion content drinking water (2.4-2.8 pH) 68046controlled hydrogen ion content drinking water (2.4-2.8 pH)
18kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat324-D1Rat156)/Eurmale10%controlled hydrogen ion content drinking water (2.4-2.8 pH) 68047controlled hydrogen ion content drinking water (2.4-2.8 pH)
8kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat324-D1Rat156)/Eurmale41%controlled hydrogen ion content drinking water (2.4-2.8 pH) then unilateral nephrectomy then NG-nitroarginine methyl ester (11-15 mg/kg/d) (for 126 days)67961controlled hydrogen ion content drinking water (2.4-2.8 pH) unilateral nephrectomyNG-nitroarginine methyl ester (11-15 mg/kg/d) (for 126 days)
8kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale8%controlled hydrogen ion content drinking water (2.4-2.8 pH) 67950controlled hydrogen ion content drinking water (2.4-2.8 pH)
5mammary gland terminal end bud countSPRD/Ztmfemale84.6control condition66135control condition
5mammary gland terminal end bud countSPRD.WKY-(D5Rat190-D5Rat114)/Ibmmfemale59.3control condition66136control condition
5mammary gland terminal end bud countSPRD.WKY-(D18Wox8-D18Rat44)/Ibmmfemale60.3control condition66137control condition
5mammary gland terminal end bud countWKY/Ztmfemale33.8control condition66138control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurnot specified15%unilateral nephrectomy68874unilateral nephrectomy
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat384-D1Rat156)/Eurnot specified13%unilateral nephrectomy68875unilateral nephrectomy
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eurnot specified30%unilateral nephrectomy68876unilateral nephrectomy
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eurnot specified12%unilateral nephrectomy68877unilateral nephrectomy
12kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurnot specified8%control condition68878control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat384-D1Rat156)/Eurnot specified14%control condition68879control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eurnot specified21%control condition68880control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eurnot specified8%control condition68881control condition
12kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurnot specified20%unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days)68882unilateral nephrectomyNG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days)
11kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat384-D1Rat156)/Eurnot specified42%unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days)68883unilateral nephrectomyNG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days)
9kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eurnot specified29%unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days)68885unilateral nephrectomyNG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurnot specified11%NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days)68886NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat384-D1Rat156)/Eurnot specified20%NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days)68887NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eurnot specified33%NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days)68888NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days)
2kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Mit18-D1Mit8)(D14Mit11-D14Hmgc14b)(D14Rat65-D14Rat90)/Eurnot specified59%unilateral nephrectomy then NG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days)68884unilateral nephrectomyNG-nitroarginine methyl ester (10-21 mg/kg/d) (for 126 days)
12kidney sclerotic glomeruli count to total glomeruli count ratioACI.FHH-(D1Rat384-D1Rat452)(D17Rat61-D1Arb5)(D17Rat51)/Eurnot specified14%NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days)68889NG-nitroarginine methyl ester (9-16 mg/kg/d) (for 126 days)
20percentage of study population developing hematuria during a period of timeLOU/Insmale0%control condition68637control condition
60percentage of study population developing hematuria during a period of timeBN/Rjmale16.7%control condition68638control condition
9motile sperm count to total sperm count ratioSHR/OlaIpcvmale57%control condition69015control condition
9motile sperm count to total sperm count ratioBN-Lx/Cubmale67%control condition69016control condition
9normal sperm count to total sperm count ratioSHR/OlaIpcvmale80.2%control condition69021control condition
9normal sperm count to total sperm count ratioBN-Lx/Cubmale84.8%control condition69022control condition
4percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeLEW.BN-(D10Rat43-D10Mco4)/Rjboth0%Toxoplasma gondii cysts (20 null) (for 42 days)75681Toxoplasma gondii cysts (20 null) (for 42 days)
3percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeLEW.BN-(D10Mco17-D10Mco14)/Cimlboth0%Toxoplasma gondii cysts (20 null) (for 42 days)75682Toxoplasma gondii cysts (20 null) (for 42 days)
3percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeLEW.BN-(D10Mco17-D10Rat221)/Cimlboth66.67%Toxoplasma gondii cysts (20 null) (for 42 days)75683Toxoplasma gondii cysts (20 null) (for 42 days)
4percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeLEW.BN-(D10Arb4-D10Rat133)/Cimlboth75%Toxoplasma gondii cysts (20 null) (for 42 days)75684Toxoplasma gondii cysts (20 null) (for 42 days)
4percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeLEW.BN-(D10Mgh7-D10Rat221)/Cimlboth100%Toxoplasma gondii cysts (20 null) (for 42 days)75685Toxoplasma gondii cysts (20 null) (for 42 days)
4percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeLEW.BN-(D10Rat32-D10Rat133)/Cimlboth75%Toxoplasma gondii cysts (20 null) (for 42 days)75686Toxoplasma gondii cysts (20 null) (for 42 days)
3percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeLEW.BN-(D10Mco17-D10Rat133)/Cimlboth100%Toxoplasma gondii cysts (20 null) (for 42 days)75687Toxoplasma gondii cysts (20 null) (for 42 days)
5percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeBN.LEW-(D10Rat32-D10Mgh4)/Rjboth0%Toxoplasma gondii cysts (20 null) (for 42 days)75688Toxoplasma gondii cysts (20 null) (for 42 days)
5percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeBN.LEW-(D10Mco17-D10Mco14)/Cimlboth40%Toxoplasma gondii cysts (20 null) (for 42 days)75689Toxoplasma gondii cysts (20 null) (for 42 days)
5percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeBN.LEW-(D10Mco17-D10Rat80)/Cimlboth0%Toxoplasma gondii cysts (20 null) (for 42 days)75690Toxoplasma gondii cysts (20 null) (for 42 days)
5percentage of study population displaying Toxoplasma gondii brain cysts at a point in timeBN.LEW-(D10Rat32-D10Rat133)/Cimlboth0%Toxoplasma gondii cysts (20 null) (for 42 days)75691Toxoplasma gondii cysts (20 null) (for 42 days)
6percentage of study population developing pituitary gland hyperplastic lesions during a period of timeBN/SsNHsdnot specified100%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69908diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary gland hyperplastic lesions during a period of timeF344/NHsdnot specified0%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69912diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary gland hyperplastic lesions during a period of timeF344.BN-(D5Rat1-D5Mit5)/Dlwnot specified0%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69916diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that replace a portion of the gland during a period of timeBN/SsNHsdnot specified0%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69909diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that replace a portion of the gland during a period of timeF344/NHsdnot specified50%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69913diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that replace a portion of the gland during a period of timeF344.BN-(D5Rat1-D5Mit5)/Dlwnot specified67%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69917diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that replace the entire gland during a period of timeBN/SsNHsdnot specified0%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69910diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that replace the entire gland during a period of timeF344/NHsdnot specified50%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69914diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that replace the entire gland during a period of timeF344.BN-(D5Rat1-D5Mit5)/Dlwnot specified33%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69918diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that invade the glandular capsule during a period of timeBN/SsNHsdnot specified0%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69911diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that invade the glandular capsule during a period of timeF344/NHsdnot specified50%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69915diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6percentage of study population developing pituitary tumors that invade the glandular capsule during a period of timeF344.BN-(D5Rat1-D5Mit5)/Dlwnot specified67%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69919diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
6lactotroph count to total pituicyte count ratio in prolactinomaF344.BN-(D5Rat1-D5Mit5)/Dlwnot specified86%diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days)69920diethylstilbestrol (5 mg) (for 70 days)surgical implantation (for 70 days)
20percentage of study population developing benign colorectal tumors during a period of timeWF/CrCrlinot specified25%1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703751,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20percentage of study population developing benign colorectal tumors during a period of timeACI/SegHsdnot specified75%1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703761,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20benign colorectal tumor numberWF/CrCrlinot specified0.251,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703771,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20benign colorectal tumor numberACI/SegHsdnot specified1.51,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703781,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20poorly differentiated malignant colorectal tumor numberWF/CrCrlinot specified1.081,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703851,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20poorly differentiated malignant colorectal tumor numberWF/CrCrlinot specified0.211,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703861,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20percentage of study population developing poorly differentiated malignant colorectal tumors during a period of timeWF/CrCrlinot specified80%1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703831,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20percentage of study population developing poorly differentiated malignant colorectal tumors during a period of timeACI/SegHsdnot specified15%1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703841,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20well differentiated malignant colorectal tumor numberACI/SegHsdnot specified0.281,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703811,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20well differentiated malignant colorectal tumor numberWF/CrCrlinot specified0.161,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703821,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20percentage of study population developing well differentiated malignant colorectal tumors during a period of timeWF/CrCrlinot specified15%1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703791,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
20percentage of study population developing well differentiated malignant colorectal tumors during a period of timeACI/SegHsdnot specified20%1,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)703801,2-dimethylhydrazine (20 mg/kg/week) (for 182 days)
21kidney sclerotic glomeruli count to total glomeruli count ratioACI/Eurmale3.2%unilateral nephrectomy69158unilateral nephrectomy
26kidney sclerotic glomeruli count to total glomeruli count ratioFHH/Eurmale52.1%unilateral nephrectomy69159unilateral nephrectomy
30percentage of study population developing cerebrovascular lesions during a period of timeSHRSP/Bbbboth100%controlled sodium content diet (3.7 mg/g) (for 42 days) and controlled sodium content drinking water (1 %) (for 42 days) and controlled potassium content diet (6.3 mg/g) (for 42 days)69117controlled sodium content diet (3.7 mg/g) (for 42 days)controlled sodium content drinking water (1 %) (for 42 days)controlled potassium content diet (6.3 mg/g) (for 42 days)
30percentage of study population developing cerebrovascular lesions during a period of timeSHR/Bbbboth20%controlled sodium content diet (3.7 mg/g) (for 140 days) and controlled sodium content drinking water (1 %) (for 140 days) and controlled potassium content diet (6.3 mg/g) (for 140 days)69118controlled sodium content diet (3.7 mg/g) (for 140 days)controlled sodium content drinking water (1 %) (for 140 days)controlled potassium content diet (6.3 mg/g) (for 140 days)
31percentage of study population developing cerebrovascular lesions during a period of timeSHRSP/Bbbnot specified100%controlled sodium content diet (3.7 mg/g) (between 70 and 88 days) and controlled sodium content drinking water (1 %) (between 70 and 88 days) and controlled potassium content diet (6.3 mg/g) (between 70 and 88 days)69119controlled sodium content diet (3.7 mg/g) (between 70 and 88 days)controlled sodium content drinking water (1 %) (between 70 and 88 days)controlled potassium content diet (6.3 mg/g) (between 70 and 88 days)
18percentage of study population developing cerebrovascular lesions during a period of timeSHRSR/Bbbnot specified0%controlled sodium content diet (3.7 mg/g) (for 84 days) and controlled sodium content drinking water (1 %) (for 84 days) and controlled potassium content diet (6.3 mg/g) (for 84 days)69120controlled sodium content diet (3.7 mg/g) (for 84 days)controlled sodium content drinking water (1 %) (for 84 days)controlled potassium content diet (6.3 mg/g) (for 84 days)
20percentage of study population developing cerebrovascular lesions during a period of timeSHRSP.SHRSR-(Klk1-Mt1-ps1)/Bbbnot specified61%controlled sodium content diet (3.7 mg/g) (between 28 and 49 days) and controlled sodium content drinking water (1 %) (between 28 and 49 days) and controlled potassium content diet (6.3 mg/g) (between 28 and 49 days)69121controlled sodium content diet (3.7 mg/g) (between 28 and 49 days)controlled sodium content drinking water (1 %) (between 28 and 49 days)controlled potassium content diet (6.3 mg/g) (between 28 and 49 days)
34percentage of study population developing cerebrovascular lesions during a period of timeSHRSP.SHRSR-(D1Rat134-Mt1-ps1)/Bbbnot specified63%controlled sodium content diet (3.7 mg/g) (between 28 and 49 days) and controlled sodium content drinking water (1 %) (between 28 and 49 days) and controlled potassium content diet (6.3 mg/g) (between 28 and 49 days)69122controlled sodium content diet (3.7 mg/g) (between 28 and 49 days)controlled sodium content drinking water (1 %) (between 28 and 49 days)controlled potassium content diet (6.3 mg/g) (between 28 and 49 days)
33percentage of study population developing cerebrovascular lesions during a period of timeSHRSR.SHRSP-(Klk1-Mt1-ps1)/Bbbnot specified20%controlled sodium content diet (3.7 mg/g) (between 42 and 91 days) and controlled sodium content drinking water (1 %) (between 42 and 91 days) and controlled potassium content diet (6.3 mg/g) (between 42 and 91 days)69123controlled sodium content diet (3.7 mg/g) (between 42 and 91 days)controlled sodium content drinking water (1 %) (between 42 and 91 days)controlled potassium content diet (6.3 mg/g) (between 42 and 91 days)
31percentage of study population developing cerebrovascular lesions during a period of timeSHRSR.SHRSP-(D1Rat134-Mt1-ps1)/Bbbnot specified20%controlled sodium content diet (3.7 mg/g) (between 42 and 91 days) and controlled sodium content drinking water (1 %) (between 42 and 91 days) and controlled potassium content diet (6.3 mg/g) (between 42 and 91 days)69124controlled sodium content diet (3.7 mg/g) (between 42 and 91 days)controlled sodium content drinking water (1 %) (between 42 and 91 days)controlled potassium content diet (6.3 mg/g) (between 42 and 91 days)
33percentage of study population developing cerebrovascular lesions during a period of timeSHRSP.SHRSR-(Klk1-Mt1-ps1)/Bbbnot specified100%controlled sodium content diet (3.7 mg/g) (between 28 and 67 days) and controlled sodium content drinking water (1 %) (between 28 and 67 days) and controlled potassium content diet (6.3 mg/g) (between 28 and 67 days)84575controlled sodium content diet (3.7 mg/g) (between 28 and 67 days)controlled sodium content drinking water (1 %) (between 28 and 67 days)controlled potassium content diet (6.3 mg/g) (between 28 and 67 days)
35percentage of study population developing cerebrovascular lesions during a period of timeSHRSP.SHRSR-(D1Rat134-Mt1-ps1)/Bbbnot specified100%controlled sodium content diet (3.7 mg/g) (between 28 and 91 days) and controlled sodium content drinking water (1 %) (between 28 and 91 days) and controlled potassium content diet (6.3 mg/g) (between 28 and 91 days)84576controlled sodium content diet (3.7 mg/g) (between 28 and 91 days)controlled sodium content drinking water (1 %) (between 28 and 91 days)controlled potassium content diet (6.3 mg/g) (between 28 and 91 days)
7number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteriesBN/Rjmale59.4control condition96767control condition
3number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteriesBN/Rjfemale36.3control condition96768control condition
3number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteriesLOU/MBbbfemale0control condition97049control condition
8number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteriesLOU/MBbbmale0control condition97048control condition
7number of ruptures of the internal elastic lamina of the renal arteriesBN/Rjmale2.14control condition96771control condition
8number of ruptures of the internal elastic lamina of the renal arteriesLOU/MBbbmale0.13control condition96777control condition
3number of ruptures of the internal elastic lamina of the renal arteriesBN/Rjfemale0.33control condition96772control condition
8number of ruptures of the internal elastic lamina of the renal arteriesLOU/MBbbfemale0control condition97047control condition
7arterial internal elastic lamina rupture composite scoreBN/Rjmale118.7control condition96769control condition
3arterial internal elastic lamina rupture composite scoreBN/Rjfemale65control condition96770control condition
3arterial internal elastic lamina rupture composite scoreLOU/MBbbfemale0control condition97051control condition
8arterial internal elastic lamina rupture composite scoreLOU/MBbbmale0control condition97050control condition
10patent ductus arteriosus scoreLOU/MBbbfemale0.17control condition96776control condition
61patent ductus arteriosus scoreBN/Rjmale3.78control condition96773control condition
3patent ductus arteriosus scoreBN/Rjfemale4control condition96774control condition
27patent ductus arteriosus scoreLOU/MBbbmale0.28control condition96775control condition

Contact Us |  About Us |  Jobs at RGD